semaglutide nash phase 3 essence ESSENCE: bests placebo in MASH resolution, fibrosis improvement at 72 weeks Phase 3 Trial of Semaglutide
Description
The platform's internal data indicates that inquiry volume regarding needle-free options has increased substantially as patient awareness of oral alternatives has grown, suggesting significant unmet demand within populations previously excluded from GLP-1 therapy consideration
However, those who aren't eligible after testing as well as those who can no longer afford medication are able to cancel
Bagsvaerd, Denmark: Novo Nordisk A/S (2023)
Patients should never start, stop, or combine these medications without explicit guidance from their prescribing clinician
Doyle ME, and Egan JM
